Atypical Presentation of Glioblastoma Multiforme by Al-Janabi, Wissam et al.
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2018_000954 European Journal of Case Reports in Internal Medicine © EFIM 2018
Doi: 10.12890/2018_000945- European Journal of Case Reports in Internal Medicine - © EFIM 2018
Atypical Presentation of Glioblastoma Multiforme
Wissam Al-Janabi, Renee Krebs, Ximena Arcila-Londono, Iram Zaman, Bashiruddin K. Ahmad




How to cite this article: Al-Janabi W, Krebs R, Arcila-Londono X, Zaman I, Ahmad BK. Atypical presentation of glioblastoma multiforme. EJCRIM 2018;5: 
doi:10.12890/2018_000954.
Conflicts of Interests: The Authors declare that there are no competing interests.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License
ABSTRACT
Background: Glioblastoma multiforme (GBM) is a highly malignant glial tumour classified by the World Health Organization (WHO) as a stage 
IV astrocytoma. It varies in shape and size and can be cystic, vascular and necrotic. It often appears as a ring-enhancing lesion on magnetic 
resonance imaging (MRI). The most common symptoms of GBM, such as headache, vomiting and seizures, are due to increased intracranial 
pressure. The objective of this case report is to describe an atypical presentation of GBM.
Case Report: A 53-year-old woman of Italian origin presented with a 2-week history of lack of coordination in her hands and some difficulty in 
speech. Electromyography for assessment of her arms and cranial bulbar function was normal. However, 2 days later, the patient presented 
to the emergency department with progressive weakness in her left arm and leg as well as difficulty in speech. Mild left facial asymmetry 
was noted. A brain MRI revealed a right frontal mass. Stereotactic surgical resection was performed 2 days later, and biopsy confirmed the 
diagnosis of GBM. Although headache and other features of raised intracranial pressure are the most common initial symptoms of GBM, any 
atypical neurological or psychiatric presentation in an adult patient should raise suspicion for this tumour.
Conclusion: Careful analysis of an adult with atypical signs and symptoms along with thorough review of radiological tests will facilitate early 
diagnosis of dangerous tumours such as GBM.
LEARNING POINT
• An adult patient with symptoms that do not conform to a neurological condition should be investigated for a brain tumour.
• Careful history taking and examination are essential for reaching the correct diagnosis as soon as possible.
• Meticulous review of radiological images in order to detect subtle changes in brain anatomy is essential.
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BACKGROUND
Glioblastoma multiforme (GBM) is a primary brain tumour which is characterized by a rapidly growing mass that varies in size and shape, 
and accounts for 70% of all primary brain tumours. It is classified by the WHO as a highly malignant tumour[1–3]. Although GBM may present 
as multiple lesions, it is usually a just single mass[2]. Headache, vomiting and seizure are the most common presentations[2,4,5]. The GBM can 
double in size in 2 days to several weeks, which gives it a dire prognosis, with a median survival time of 9.9 months if treated with surgery 
and radiotherapy with or without chemotherapy. It is twice as common in white as in black patients[2,5–7] and is also slightly more frequent in 
males than females. It is often located in the supratentorial region of the brain with extensive necrosis[5,6]. 
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About 5% of patients with GBM have a family history, and some cases are linked to rare syndromes, such as Li-Fraumeni syndrome, 
neurofibromatosis I and II, or Turcot’s syndrome[6]. If the GBM tumour involves the corpus callosum, then it is called ‘butterfly glioma’, and 
usually metastasizes to the occipital and temporal lobes bilaterally[2,6]. Good prognostic features for GBM are younger age, lateral tumour 
localization, complete macroscopic resection, and abundant giant cells (gigantocellular glioblastoma)[7,8]. The brain MRI may not show 
a typical mass. Indeed, deceiving features of a demyelinating process may be seen. Hence GBM should be considered in a middle-aged 
patient with an atypical presentation who does not respond to the usual treatment for the suspected condition[9]. GBM can also occur in 
octogenarians[10]. If GBM is suspected in a patient where resection is not feasible, a fine needle biopsy is recommended to reduce trauma[11,12]. 
GBM can spread directly to adjacent parts of the brain or extracranially via the CSF[13]. Both GBM and its treatment can cause neurological, 
cognitive or psychiatric symptoms[14].
CASE REPORT
A 53-year-old woman presented to her primary care physician complaining of feeling anxious, with panic at times. She was having difficulty 
finding words and had bilateral hand and wrist pain, which had largely improved although there was still some lack of coordination. She 
also had trouble getting out of the bed and getting dressed. However, she denied headache, nausea or vomiting. The patient described her 
anxiety symptoms as insomnia, shortness of breath and feeling ‘closed in’. She had experienced these symptoms for a few years but they 
had got worse over the past month. She denied suicidal and homicidal ideation. The patient felt more comfortable sleeping during the day, 
but this caused her to stay up late at night. She had a past medical history of allergic rhinitis, asthma, hyperglycaemia and hyperlipidaemia. 
She had a positive family history of anxiety. Physical examination showed normal vital signs, mild nasal congestion, quiet and clear speech, 
possible mild bilateral thenar atrophy, a mildly positive Phalen’s test, and a negative Tinel sign. Mild left facial asymmetry was also noted. 
Electromyography was normal.
Two days later, the patient presented to the emergency department complaining of progressive left-sided weakness and difficulty in speech. 
A CT scan of the head to rule out stroke surprisingly showed a mass in the right frontal lobe. MRI confirmed the presence of this mass which 
extended to the corpus callosum. The mass measured 5.7 cm by 3.8 cm (Fig. 1). CT scans of the chest, abdomen and pelvis were negative for 
any metastases.
Figure 1. Magnetic 
resonance imaging clearly 
shows the right frontal 
lobe mass extending to 
the corpus callosum
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A right frontal stereotactic craniotomy revealed a multicystic, vascular, necrotic mass which was soft in many areas. Frozen sections and 
biopsy slides (Fig. 2) showed an infiltrating astrocytic tumour with necrosis, microvascular proliferation, and brisk mitotic activity. The tumour 
cells were strongly immunoreactive to GFAP, and negative for Cam 5.2 and IDH1 R132H mutant antibody. Neurofilament immunostaining 
highlighted the infiltrating nature of this tumour. P53 immunostaining showed nuclear expression in a minor subset of the tumour cells. All 
immunostaining was performed with appropriate controls on separate slides. The final diagnosis was GBM of the brain.
Figure 2. Histopathology: (1) H&E stain reveals the tumour with necrosis; (2) GFAP immunostaining is positive for tumour cells; a blood vessel with negative staining shows 
microvascular proliferation; (3) MIB-1 immunostaining of numerous tumour cells. Molecular information: MIB proliferation index 20%. IDH1 R123H (IHC): negative. IDH1 (NGS): 
negative; EGFRvIII mutation: negative; MGMT promoter methylation: negative
DISCUSSION
The first case of GBM was reported in 1880 by Bradley[13]. GBM is one of the deadliest adult tumours and has a grave prognosis[1,2]. Although 
it usually presents as a supratentorial tumour, rare cases involving the brainstem and cerebellum have been reported[9,10]. Owing to its shape 
on MRI, which is often described as a ring-enhancing lesion, GBM is sometimes misdiagnosed as an infection or inflammatory process[1,9]. 
GBM is highly metastatic via CSF or spread to adjacent regions[1,13]. In the present case, only a single large right frontal mass was identified, 
with all other screening for satellite lesions being negative. The corpus callosum was involved in this case, but no hydrocephalus or raised 
intracranial pressure was detected. The swift progression of the patient’s symptoms might have been due to rapid growth of the GBM 
mass. Previous studies have shown that it can take from only 2 days to several weeks for the tumour to double in size[7]. Patients survival 
time is also related to tumour doubling time[7,8]. Patients with glioma can exhibit psychiatric symptoms, such as personality and behavioural 
changes, hallucinations, mood issues or even psychosis[14]. In the present case, the patient’s initial complaints of anxiety, left-hand lack of 
coordination (which developed into left-hand weakness) and difficulty in speech were unlike the usual symptoms of brain tumour patients 
(early morning headache, vomiting or vision disturbance) and more like those of motor neuron disease (MND). However, the patient’s EMG 
result ruled out MND and a CT scan 2 days later revealed the GBM mass in the right frontal lobe. The patient is still alive until this moment.
CONCLUSION
A careful history taking and physical examination of patients with atypical neurological, cognitive or psychiatric symptoms that do not 
conform with known neurological or psychiatric disorders along with meticulous review of any radiological tests will help early detection 
of serious tumours. Neurologists should always keep GBM in mind, especially when a patient presents with unusual symptoms that do not 
suggest well-known neurological conditions. 
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